Oncology Central

Determination of synthetic lethal interactions to provide therapeutic direction to end aggressive prostate cancer


Emergence of aggressive prostate cancer (PCa) phenotypes resistant to current available therapies is a significant clinical problem, and novel therapeutic strategies are urgently required. Androgen receptor (AR) action is a key mediator underlying development and progression of PCa. For this reason, androgen deprivation therapy has been a primary standard of care for men for over 70 years with symptomatic, advanced PCa [1]. Unfortunately, ensuing resistance to therapy is inevitable, and men will eventually develop castration-resistant PCa (CRPC).

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.